A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Q 122 (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Proof of concept; Therapeutic Use
- Sponsors QUE Oncology
- 05 Sep 2019 Planned End Date changed from 1 Jun 2020 to 1 Feb 2020.
- 05 Sep 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Nov 2019.
- 03 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Jun 2020.